Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single canter preliminary experience by Tan, HP et al.
Living-Related Donor Renal Transplantation in HIV + 
Recipients using Alemtuzumab Preconditioning and 
Steroid-Free Tacrolimus Monotherapy: ......," 611 
A Single Center Preliminary Experience <- L , 
Henkie P. Tan, 1.2 David]. Kaczorowski, I Amit Basu, 1 Akhtar Khan, 1 Jerry McCauley, 1 Amadeo Marcos, 1 
John]. Fung,1 Thomas E. Starzl, I and Ron Shapiro1 
Background. End-stage renal disease (ESRD) is an increasing problem in patients infected with the human immuno-
deficiency virus (HIV). The use of highly active antiretroviral therapy (HAART) has decreased the morbidity associated 
with HIV and has prompted renewed interest in renal transplantation. 
Methods. We performed four cases of deceased donor renal transplantation in HIV + recipients and three cases where 
laparoscopic live donor nephrectomy (LLDN) was utilized to obtain the kidney for transplantation into living-related 
HIV + recipients. In the four deceased donor cases, conventional tacrolimus-based immunosuppression, without 
antibody induction was used. In the three living-related cases, the immunosuppressive regimen was based on two 
principles: recipient pretreatment and minimal posttransplant immunosuppression. Alemtuzumab 30 mg (Campath 
1-H) was used for preconditioning followed by low-dose tacrolimus monotherapy. 
Results. Of the four deceased donor cases, one patient continues to have good graft function, and another is not yet on 
dialysis but has significant graft dysfunction. Rejection was observed in three patients (75%). Infectious complications 
occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining. In the three living-
related cases, all had good graft function, and none have experienced acute rejection. HIV viral loads remain undetect-
able. CD4 counts are slowly recovering. No infectious or surgical complications occurred. There were no deaths in 
either group. 
Conclusions. These data suggest that living-related donor renal transplantation with steroid-free tacrolimus mono-
therapy in a "tolerogenic" regimen can be efficacious. However, long-term follow-up is needed to confirm this 
observation. 
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T here are an estimated 40 million people infected with hu-
man immunodeficiency virus (HIV) around the world, 
with an incidence of 5 million new cases in 2003 (1). End-
stage renal disease (ESRD) is an increasingly common prob-
lem in this growing patient population. Furthermore, the sur-
vival of patients infected with HIV who are on chronic 
hemodialysis is poor (2). Until recently, HIV -infected pa-
tients have generally not been considered candidates for renal 
transplantation (3). Before the introduction of highly active 
antiretroviral therapy (HAART), the substantially elevated 
morbidity and mortality associated with HIV infection was 
considered a contraindication to transplantation in most cen-
ters. The use of HAART has markedly decreased the rate of 
opportunistic infection and the overall mortality (4,5). This 
has prompted renewed interest in solid organ transplantation 
in this population. 
Despite improvements in survival with the use of 
HAART, there is still an increase in morbidity and mortality 
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associated with HIV infection, and it has been difficult to 
justify the use of scarce deceased donor organs for transplan-
tation into these patients (6). The utilization ofliving-related 
donor organs represents a way of providing organs for pa-
tients infected with HIV without further depleting the already 
short supply of deceased donor organs. Since its introduction 
in 1995, laparoscopic live donor nephrectomy (LLDN) has 
been shown to have a number of advantages over the tradi-
tional open operation (7). Patients experience less postoper-
ative pain, shorter hospital stays, and shorter recovery times 
before returning to work (8, 9). 
In addition, because of the elevated risk of opportu-
nistic infection and the risk of progression to AIDS, sub-
jecting patients infected with HIV to pharmacologic im-
munosuppression has raised some concerns about the 
safety of renal transplantation in these patients. The avoid-
ance of posttransplant over-immunosuppression is 
thought to permit the induction of partial tolerance (10). 
Recent data demonstrate that recipient pretreatment with 
rabbit anti-thymocyte globulin (Thymoglobulin), aT-cell 
depleting agent, followed by minimal use of posttransplant 
immunosuppression, permits a dramatic ability to wean 
immunosuppression (J 0, 11). More recently, precondi-
tioning with alemtuzumab (Campath-lH, Millennium 
Pharmaceuticals, Cambridge, MA), a humanized anti-
CD52 monoclonal antibody (12, 13), has been used instead 
of Thymoglobulin (14), with excellent early outcomes. A 
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similar approach may be of benefit in HIV + patients by permit-
ting the weaning of maintenance immunosuppression. 
Here we present a total of seven consecutive cases of 
HIV + patients who underwent renal transplantation at the 
University of Pittsburgh Medical Center from 1998 to the 
present. All seven patients had undetectable viral loads and 
CD4 counts over 200 cells/mm3 before transplantation. Four 
deceased donor recipients and three cases where LLDN was 
utilized to obtain the kidney for transplantation into living-
related (sibling) recipients infected with HIV are described. 
MATERIALS AND METHODS 
Clinical data were collected through a detailed comput-
er-assisted chart review of the University of Pittsburgh Med-
ical Center Archive and Retrieval (MARS) and the Electronic 
Data Interface for Transplantation (EDIT) systems of the 
Thomas E. Starzl Transplantation Institute. The data collec-
tion was approved by the University of Pittsburgh Institu-
tional Review Board (IRB). The immunosuppressive regimen 
utilized in the living donor recipients was approved by the 
Innovative Practices Committee and The Pharmacy & Ther-
apeutics Committee. As this regimen represents the standard 
of care in our program for the last 3 years, the IRE has ruled 
that it does not require IRB approval. All living donors and 
recipients provided informed consent, in addition to a sepa-
rate (IRE-approved) informed consent for immune monitor-
ing studies not routinely obtained in our conventional prac-
tice. All three living donors were specifically counseled by our 
psychologists/psychiatrists. All three living donor recipients 
had their primary residence outside the state of Pennsylvania 
and were referred to us through recommendations of their 
physicians. No other potential living donor recipients were 
turned down during this time period. Four HIV + consecu-
tive recipients of deceased donor grafts between 1998 and the 
present were identified. 
Data on the recipients of living-related donor grafts 
were collected prospectively. Demographic, laboratory, and 
other data collected included age, race, gender, indication for 
transplantation, creatinine clearance, creatinine, CD4 counts 
before and after transplantation, HIV viral loads before and 
after transplantation, and tacrolimus levels. Complications in 
each group were also noted. 
Immunosuppression for the deceased donor recipients 
was a function of the immunosuppressive practices of the era 
and utilized a tacrolimus-based regimen without antibody 
induction. For recipients of living-related donor organs, the 
immunosuppressive regimen utilized pretreatment with alem-
tuzumab 30 mg intravenously (IV) premedicated by 1 gm of IV 
methylprednisolone, diphenhydramine 50 mg IV, famotidine 
20 mg IV, and acetaminophen 650 mg orally (PO), and another 
1 gm of IV methylprednisolone before reperfusion, followed by 
tacrolimus monotherapy to achieve a level of 10 nglmL for the 
first 100 days posttransplant, with subsequent tacrolimus dose 
weaning. The use of tacrolimus monotherapy (starting with an 
initial two times per day [BID J dosing to obtain an initial level of 
10 ngimLl is the standard of care for all renal transplantation 
recipients, unless contraindicated, at the University of Pitts-
burgh Medical Center for the last 2 years. All patients were taking 
HAART therapy before transplantation. HAART regimens were 
restarted for each patient after the resumption of oral intake 
Transplantation· Volume 78, Number 11, December 15, 2004 
postoperatively and managed by a dedicated HIV infectious dis-
ease specialist at UPMC and by each patient's local academic 
infectious disease physician after discharge. 
RESULTS 
Deceased Donor Renal Transplant Recipients 
Between 1998 and 2004, four consecutive HIV + pa-
tients received deceased donor renal transplants. The mean 
follow-up is 49::1:: 14 months. All of the patients were male, 
with a mean age of 45::1:: 11 years (range 32-58). Two patients 
were African-American, and two were Caucasian. All 000%) 
are alive at most recent follow-up. Only one of the four pa-
tients (25%) continues to have good graft function (creati-
nine 1.7 mg/dL), and another patient has not yet returned to 
dialysis but has a creatinine of 4 mg/ dL. Medical noncompli-
ance was a contributing factor to graft failure in the other two 
patients. 
CD4 counts and HIV viral loads were available for all 
four patients. Three of these four (75%) experienced de-
creases in their CD4 counts and one of these four patients 
(25%) experienced an increase in viral load. One patient de-
veloped plantar fasciitis and cellulitis of both lower 
extremities. 
One patient developed a periallograft hematoma re-
quiring transfusion after a biopsy. Three of the four patients 
(75%) had at least one episode of acute cellular rejection, and 
one experienced only one episode of borderline rejection. 
One patient developed a basal cell carcinoma, which was ex-
cised. No other complications were reported. Individual re-
cipient and donor demographics are detailed in Tables 1 and 
2. 
Living-Related Renal Transplant Recipients 
ease #1 
A 44-year-old Caucasian hemodialysis-dependent man 
with HIV presented for evaluation for renal transplantation 
because ofESRD secondary to type 1 diabetes mellitus in July 
2002. His medical history was notable for hypothyroidism, 
hypertension, in addition to diabetic neuropathy and reti-
nopathy. He contracted HIV in 1985 from a male sexual part-
ner. At the time of his pretransplant evaluation, his CD4 
count was 692 cells/mm3, and his viral load was undetectable. 
His serum creatinine was 4.5 mg/dL. 
In September of2003, the patient's healthy 46-year-old 
donor brother underwent a left LLDN without complication. 
The donor serum creatinine was l.0 mg/dL and creatinine 
clearance was 93 mUmin. Donor demographics are summa-
rized in Table 2. The warm ischemic time was 4.5 min. The 
kidney, which had a single renal artery, a single renal vein, and 
a single ureter, was subsequently used for transplantation 
without complication. The donor's hospital course was un-
eventful, and he was subsequently discharged home on post-
operative day 3 with a creatinine of 1.6 mg/dL. No complica-
tions have been reported to date. 
The recipient received 30 mg ofIV alemtuzumab intra-
operatively before revascularization. His postoperative 
course was uncomplicated and he was discharged home on 
postoperative day 5. His antiviral regimen is listed in Table 3. 
Approximatelv 1 month after transplant his CD4 count was 
15 cells/mm3 and is currently 147 cells/mm]. His viral load 
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TABLE 1. Demographic data on HN-infected recipients of deceased donor renal transplants at the University of 
Pittsburgh between 1998 and 2004 
Cr Cr CD4 CD4 Viral load Follow-up/' 
Recipient Age Race Indication Maintenance (lowest) (most recent) An ti -retrovirals pre-Tx post-Tx copies/mL Complications months 
58 C PKD Tacrolimus 1.6 4.0 Lamivudine, stavudine >500 482 <50 Delayed graft function, 39 
mycophenolate nevirapine Periallograft hematoma 
prednisone following biopsy, ACR, 
plantar fasciitis, cellulitis 
45 AA HTN, Tacrolimus 1.7 5.6' Lamivudine. 1,054 172 <50 Delayed graft function, S! 
DM" prednisone zidovudine, ziagen mull!ple episodes of ACR, 
mycophenolate chronic allograft 
nephropathy, dialysis 
dependent 
32 AA HTN, Tacrolimus 1.3 9.2' Lamivudine, 39J 98 5,774 Multiple episodes of ACR, 39 
HIVAN sirolimus zidovudine severe chronic rejection 
prednisone efavirenz 
4 46 C PKD Tacrolimus 1.3 1.5 Nevirapine, 411 944 <50 Basal cell carcinoma, sip 69 
lamivudine excision 
a This patient was also infected with hepatitis C. 
b Follow-up as of) uly 22, 2004. 
, On dialysis. 
stavudint> 
C, Caucasian; AA, African-American; PKD, polycystic kidney disease; FSGS, focal and segmental glomerulosclerosis; HTN, hypertension; DM, diabetes 
mellitus; HIVAN, human immunodeficiency associated nephropathy; Cr, creatinine; Tx, transplant; NA, not available; AeR, acute cellular rejection; CMV, 
cytomegalovirus. 
TABLE 2. Demographic features of deceased donors and grafts for HN-infected recipients 
Donor Donor age Kidney Anatomy 
37 Left Single artery, vein 
and ureter 
2 NA Right Single artery, vein 
and ureter 
3 22 Right Two renal 
arteries, single 
vein and ureter 
4 25 Left Single artery, vein 
and ureter 
IVDA, intravenous drug abuse; NA, not available. 
remains undetectable. His current immunosuppressive regi-
men consists of 0.1 mg of tacrolimus every 4 days (he takes a 
protease inhibitor) with most recent tacrolimus level of 3.7 
ng/mL, gradually weaned from an initial posttransplant level 
0[10.0 ng/mL. His most recent serum creatinine is 1.6 mg/dL. 
He was found to have two episodes of tacrolimus toxicity by 
biopsy for an elevated creatinine. He has not had any compli-
cations, episodes of rejection, or opportunistic infections. 
Case #2 
A 40-year-old African-American woman presented for 
evaluation for renal transplantation in May 2003. She devel-
oped ESRD secondary to hypertensive nephropathy and had 
been hemodialysis dependent since 1998. She contracted HIV 
from heterosexual contact. Her past medical history was no-
table for preeclampsia and cervical dysplasia, for which she 
underwent ablative therapy. Her CD4 count was 304 cells/ 
mm3. Her viral load was 140 copies/mL at the time of her 
initial evaluation but was undetectable at the time of her 
transplant. She had no history of opportunistic infections. 
----
Cold ischemic Immediate graft 
time function Comments 
15 hr, 3 min No High risk donor 
(IVDA) 
33 hr, 10 min No Hepatitis C positive 
donor 
24 hr, 11 min No 
19 hr, 46 min Yes 
In November 2003, the patient's 32-year-old sister who 
had sickle-cell trait but was otherwise healthy, elected to un-
dergo a left LLDN without complication. The warm ischemia 
time was 5.5 min. The donor was discharged home on post-
operative day 2 with a creatinine of 1.1 mg/dL after an unre-
markable postoperative hospital stay. She has not had any 
complications to date. 
The recipient received 30 mg of alemtuzumab intraoper-
atively. Her postoperative course was uneventful and she was 
subsequently discharged home on postoperative day 5 with cre-
atinine of 1.0 mg/dL. As oOuly of 2004, her creatinine was 1.0 
mg/dL and she was taking 16 mg of tacrolimus every other day 
with a serum tacrolimus level of 3.0 ng/mL gradually weaned 
from an initial posttransplant level of 10.0 ng/mL. Her most 
recent CD4 count is 53 cells/mm3. Her viral load has remained 
undetectable. Her current antiviral regimen is detailed in Table 
3. She had tried multiple other regimens, some of which in-
cluded protease inhibitors, but she was unable to tolerate them 
because of side effects. She has had no complications, episodes of 
rejection, or opportunistic infections to date. 
I 
i i 
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TABLE 3. Demographic data on HIV + living-related kidney recipients 
Duration of 
FK5061evei CD4 CD4 follow-up" 
Recipient Age Race Sex Indication Maintenance (mgldL) Cr Anti-retrovirals pre-Tx post-Tx Complications (days) HLA 
~~ c: ~y[ DM FK5000.1 3.7 1.0 Limivudine, 6Q7 lH Tacrulimus 325 A2,3, BUIO~I DRI6,. 7 
mg iopinavlrl ritonavir, toxicity by bx 
40 AA F HTN 
58 C M Retlux 
nephropathY 
" Follow-up as of July 22, 2004. 
I> On protease inhibitor. 
PO q 3d" 
FK506 16 mg 3.0 0.9 
POgod 
FK506 7.0 1.6 
2 mg PO bid 
abacavir, 
er"avirenz 
Lamivudi ne, 304 53 None 262 A30,36, BI8,35, DRJ,I! 
zidovudine, 
efavirenz 
Lamivudine, 1,843 39 Tacrolimus J52 A2,3, 88,-, DR!,17 
zidovudine, toxicity by bx 
efavirenz 
C, Caucasian; AA, African-American; M, male; F, female; DM, diabetes mellitus; HTN, hypertension; PO, per os; N/A, not available; bx, biopsy. 
Case #3 
In September 2002, a 58-year-old man presented for 
evaluation for renal transplantation for ESRD secondary to 
reflux nephropathy, for which he had already undergone cor-
rective surgery. He was started on peritoneal dialysis shortly 
after his evaluation. He was diagnosed with HIV approxi-
mately 5 years before his evaluation, which he contracted 
through a homosexual contact. His medical history was also 
notable for insulin-dependent diabetes mellitus, hyperten-
sion, and biliary pancreatitis, for which he previously under-
went cholecystectomy. Before transplantation, he also had 
basal cell cancer of his face and squamous cell cancer of his 
back, which were both successfully excised. His CD4 count 
was 1,843 ceIls!mm3 before transplantation, and his viral load 
was undetectable. 
In February 2004, his healthy 56-year-old sister elected 
to undergo an uncomplicated left LLDN. Her creatinine was 
0.6 mg/dL at the time. She was found to have two renal arter-
ies. One of the renal arteries supplying the upper pole was 
approximately 1 mm in diameter and was ligated. Otherwise, 
the kidney had one vein and one ureter. The warm ischemic 
time was approximately 5 min. The donor was subsequently 
discharged home on postoperative day 3 with a creatinine of 
0,9 mg/dL. She has had no complications to date. 
The recipient received 30 mg alemtuzumab before re-
vascularization. The recipient's peri- and postoperative 
course was uneventful and he was discharged home on post-
operative day 4 with a creatinine of 1.0 mg/dL. His immuno-
supFressive regimen currently consists of tacrolimus 4 mg 
once daily, His most recent tacrolimus level was 7.0 ng/mL. 
On postoperative day 14, his creatinine rose to 1.3 mg/dL and 
was 1.6 mg! dL on postoperative day 21. It has subsequently 
remained stable at 1.6 mg/dL. On multiple biopsies, there has 
been no evidence of acute cellular rejection. There was some 
subcapsular fibrous tissue with focal nonspecific mixed in-
flammation. There was also tubular vacuolization compatible 
with tacrolimus toxicity in spite of initial posttransplant levels 
of about 10 ng/mL. Otherwise, he has had no infectious or 
surgical complications and is doing well. 
DISCUSSION 
The survival of patients with HIV infection and ESRD 
receiving hemodialysis has improved compared with the uni-
formly dismal outcomes in the 1980s. Ifudu and colleagues 
found that, with 68-months follow-up, 50% (17/34) of pa-
tients with both ESRD and HIV infection were deceased, 
comparable with the mortality of patients (651131) with 
ESRD alone (15). However, when the data were adjusted for 
age, patients with both ESRD and HIV infection had a 97% 
higher risk of death than did their counterparts with ESRD 
alone. 
Recent data demonstrate that recipient pretreatment 
with Thymoglobulin, aT-cell depleting agent followed by 
minimal use of posttransplant immunosuppression, permits 
a dramatic ability to wean immunosuppression (10, 11, 14), 
and similar findings have been demonstrated using alemtu-
zumab preconditioning (13). The exact mechanism remains 
to be elucidated and we are in the process of elucidating this 
high frequency of profound in vitro hyporesponsiveness in-
duced by alemtuzumab preconditioning (16). It is also 
known that lymphopenia is followed by spontaneous homeo-
static expansion of the remaining T-cell pool size. Recently, 
Dummer and colleagues demonstrated that T-cell homeo-
static proliferation elicits effective antitumor autoimmunity 
TABLE 4. Characteristics of donors undergoing LLDN for transplantation into HIV + recipients 
Kidney Cr prior to Cr post- Days 
Donor Age Sex Race donated LLDN LLDN hospitalized Complications HLA 
46 \1 E~ Left '.U 1.6 3 None A3,24, B8,35, DRI6,ll 
2 _,2 F AA Left 0.7 1.1 2 None AI,74, B58,72, DR8,1l 
5fJ F C Left G.b 0.9 3 None 1\2,-, B35,60, DRl,; 
\1, male; F, female; C, Callcasian; .\A, .\(rican-American; Cr. creatinine; LLDN, laparoscopic live donor nephrectomy. 
-
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(17l.1t can be speculated that "lost" or "absent" immunitvto 
experimental tumors results during recoverv from the kind of 
T -cell depletion that is achieved with alemtuzumab. 
Transplantation of solid organs into patients v.rith HIV 
before the introduction of HAART yielded variable results. A 
number of reports described cases with varying degrees of suc-
cess. In 1990, Tzakis and colleagues (18) performed a retrospec-
tive analysis of25 solid organ transplant recipients at the Univer-
sity of Pittsburgh between 1981 and 1988, with a mean tollow-up 
of2.75 years (range 0.7-6.6 years). Five of the 25 patients were 
recipients of kidney transplants. The other organs were liver 
(n = 10) or heart (n= 5 J. Four out of the five kidnev transplant 
recipients were alive at follow-up. Overall, the time to the devel-
opment of AIDS appeared to be shortened after receiving an 
organ transplant and immunosuppression, but the difference 
was not statistically significant. 
Erice and colleagues from the University of lvlinnesota 
in 1991 reported five cases and reviewed the literature (19). 
They included a total of 11 recipients of kidney transplants 
that were HIV + at the time of transplant. They found that six 
of eight (75%) of these patients had functioning grafts after a 
mean follow-up of over 30 months. Eight of the patients had 
no progression of HIV or HIV -related diseases, but three of 
the patients developed AIDS and died within 2 years of trans-
plant. Another patient died of sepsis that was thought to be 
unrelated to HIV approximately 2 months after transplant. 
In 1993, a group from Germany reported four cases of 
patients that were infected with HIV through renal transplan-
tation from HIV + donors (20). Although they experienced 
several infectious complications and multiple episodes of re-
jection, none of the patients in their series developed AIDS. In 
addition to reporting these four cases, they reviewed case re-
ports of 53 patients in the literature. Interestingly, they found 
that the cumulative incidence of AIDS was significantly lower 
in HIV -infected transplant recipients that had an immuno-
suppressive regimen that included cyclosporine. 
A historical cohort analysis using data from the United 
States Renal Data System (USRDS) on solitary cadaveric renal 
transplant recipients between 1987 and 1997 was performed 
to determine the impact of HI V infection on graft and patient 
survival (21). Compared with the national USRDS transplant 
population, the HIV + patients had better HLA matching and 
younger donors. However, both patient and 3-year graft sur-
vival were reduced in HIV + patients (83% patient, 53% 
graft) compared with the USRDS population (88% patient, 
73% graft). 
Since the introduction of HAART, results have been 
more encouraging. A recent pilot trial reported 100% sur-
vival, all with functioning grafts, at a me3n follow-up of 480 
days in 10 patients undergoing renal transplantation (22). No 
adverse effect of HIV on graft function was observed in this 
study. While CD4 counts generally dropped transiently in all 
patients immediately after transplantation, they soon re-
turned to normal levels. However, in all patients treated with 
Thymoglobulin, CD4 counts dropped below 220 and have 
been slow to recover. Reiection occurred in 5 of 10 (50% J 
kidner transplant recipients, and 3 of the 5 required Thvmo-
globulin to treat the rejection. No AIDS defining infections 
occurred in this series. However, one patient developed 
Staphylococcus CltIJ"CUS endocarditis, and another developed 
Psucdomonas aerogillosa pneumonia and sepsis after treat-
Tan et a1. 1687 
ment with Thymoglohulin. There were also two cases of S. 
aLlreU5 wound infections and one case of influenza B pneu-
monia. With a longer mean follow-up of23 months, the same 
investigators found unexpectedly high incidence of rejection 
in 67% ofHIV + recipients of renal transplants using a cyclo-
sporine, mvcophenolate mofetil, and steroid maintenance 
immunosuppression protocol (23). 
In the recipients of deceased donor organs that we have 
reported here, the incidence of rejection was also high (75%) 
using conventional tacrolimus-based immunosuppression 
without antibody induction. Chronic allograft nephropathy 
was also a significant problem. These observations, coupled 
with the occurrence of multiple infectious complications in 
these patients, suggest that further investigation into novel 
approaches to renal transplantation in HIV + recipients was 
warranted. 
In contrast to these results, all three of the patients pre-
sented here who received living-related donor grafts under a 
tolerogenic immunosuppressive regimen are doing well with 
functioning grafts to date, albeit with a short follow-up. As 
expected, because of pretreatment with alemtuzumab, each 
of the patients has experienced a drop in CD4 count, but they 
appear to be recovering. Importantly, although the follow-up 
is short, we have not observed any infectious complications or 
graft rejection in this group receiving posttransplant steroid-
free tacrolimus mono therapy. In addition, HIV viral loads 
have remained undetectable. These initial results are encour-
aging. None of the donors have had any surgical complica-
tions after undergoing LLDN. While long-term follow-up 
will be needed, the data presented here suggest that LLDN is 
an effective means for providing organs for patients with 
ESRD who are infected with HIV who otherwise would be on 
a potentially controversial deceased donor waiting list and 
that a "tolerogenic" regimen involving pretreatment with ale-
mtuzumab and posttransplant immunosuppression with 
low-dose tacrolimus monotherapy seems to be safe and effec-
tive for the prevention of graft rejection. We believe that our 
immunosuppression protocol will also benefit the HIV + re-
cipients who will receive deceased donor organs. 
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